Key result
Diabetes linked to ~73% higher periprocedural mortality in STEMI patients undergoing primary PCI.
Why the study?
It was unclear whether the impact of diabetes mellitus on primary PCI outcomes for STEMI remains present in large, unselected patient cohorts receiving up-to-date treatment.
Does diabetes mellitus predict worse periprocedural outcomes in STEMI patients undergoing primary PCI?
Cohort (n=150,782)
Yes
Does diabetes mellitus predict worse periprocedural outcomes in STEMI patients undergoing primary PCI?
Absolute Event Rate: 1.9% vs 1.1%
p-value: p=<0.0001
Diabetes mellitus remains a strong independent predictor of periprocedural mortality in STEMI patients undergoing primary PCI, though this may be partially explained by their higher baseline risk profile.
No takes yet. Share an insight, caveat, or question.
Diabetes flags higher periprocedural mortality risk in STEMI primary PCI; leaves open independent causality and targeted interventions.
Dziewierz et al. (2022) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=150,782). Diabetes mellitus vs. No diabetes mellitus was evaluated on Periprocedural mortality (p=<0.0001). Diabetes mellitus was associated with higher periprocedural mortality compared to no diabetes in STEMI patients undergoing primary PCI (1.9% vs. 1.1%; P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: